Pulmonology Advisor

Nirmatrelvir-Ritonavir Reduces Risk for Severe COVID-19 Outcomes

Real-world data supports the use of nirmatrelvir-ritonavir in reducing the risk for severe COVID-19 outcomes among nonhospitalized patients.